STOCK TITAN

Exscientia Plc American Depositary Shares - $EXAI STOCK NEWS

Welcome to our dedicated page for Exscientia Plc American Depositary Shares news (Ticker: $EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exscientia Plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exscientia Plc American Depositary Shares's position in the market.

Rhea-AI Summary
Exscientia appoints Parker Moss as Executive Vice President, Corporate Development, to strengthen precision medicine and clinical innovation platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
none
-
Rhea-AI Summary
Exscientia announces preclinical data on LSD1 and MALT1 inhibitors at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences clinical trial AI
-
Rhea-AI Summary
Exscientia prioritizes highest value oncology targets, discontinues non-core programs. Partnered pipeline progresses with milestones achieved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
none
Rhea-AI Summary
Exscientia announces collaboration with Merck KGaA, with potential milestone payments of up to $674 million and royalties on product sales
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.47%
Tags
AI
-
Rhea-AI Summary
Exscientia plc to participate in investor conferences in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.35%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
none
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on August 10, 2023, before the open of U.S. markets. The company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. The webcast can be accessed on the company's website, and the conference call can be accessed by phone. A replay will be available on the website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings
-
Rhea-AI Summary
Exscientia initiates EXCYTE-1, a multi-centre trial in ovarian cancer to investigate the relationship between ex vivo drug response and patient clinical response. The study aims to inform future studies in other solid tumors and is conducted in collaboration with the AGO Study Group. The company's precision medicine platform combines high-content imaging and deep learning image analysis to assess drug activity at a single cell level ex vivo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.5%
Tags
management
Exscientia Plc American Depositary Shares

Nasdaq:EXAI

EXAI Rankings

EXAI Stock Data

590.17M
92.58M
26.47%
26.2%
3.45%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Oxford

About EXAI

at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.